<DOC>
	<DOCNO>NCT02865005</DOCNO>
	<brief_summary>Multi-center , double-blind , randomize , placebo-controlled trial Dapsone 5.0 % Gel treatment acne vulgaris .</brief_summary>
	<brief_title>Trial Dapsone 5.0 % Gel Treatment Acne Vulgaris</brief_title>
	<detailed_description>Multi-center , double-blind , randomize , placebo-controlled trial Dapsone 5.0 % Gel treatment acne vulgaris 84 day male female subject age 12-40 .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Healthy male nonpregnant female age ≥ 12 ≤ 40 year age clinical diagnosis acne vulgaris . Informed Consent/Assent : For subject 12 17 year age inclusive must provide Institutional Review Board ( IRB ) approve write assent must accompany IRB approve write consent subject 's legally acceptable representative ( i.e. , parent guardian ) . In addition , subject legally acceptable representative must sign Health Insurance Portability Accountability Act ( HIPAA ) authorization . On face , subject must ≥ 20 inflammatory lesion ( i.e. , papule pustule ) , AND ≥ 25 noninflammatory lesion ( open close comedo ) AND ≤ 2 nodulocystic lesion ( i.e. , nodule cyst ) . For purpose study treatment evaluation , lesion face count , include nose . Subjects may acne lesion area body ( e.g. , back , chest , arm ) exclude count , treatment IGA evaluation . Subjects must acne severity grade 3 4 per IGA Subjects must willing refrain use topical acne medication antibiotics 12week treatment period study drug . Prior current concomitant therapy would interfere assessment study . Prior current concomitant therapy skin condition would interfere assessment study . Prior , current plan procedure would interfere assessment study . Current planned activity would interfere assessment study . Subjects Baseline local skin site reaction score 3 [ severe ( marked/intense ) ] sign and/or symptom irritation score use local skin site reaction score .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>